Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals (NASDAQ: IONS) announced participation in upcoming investor conferences, enhancing its visibility in the healthcare sector.

Rhea-AI Summary

Ionis Pharmaceuticals (NASDAQ: IONS) announced participation in upcoming investor conferences, enhancing its visibility in the healthcare sector. Notable events include the Guggenheim Virtual Genomic Medicines and Rare Disease Days on April 4, 2023, and the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023. A live webcast of the presentations will be available on the Ionis website, with replays accessible within 48 hours.

With over 30 years in RNA-targeted therapy, Ionis is a leader in genetic medicine, possessing three marketed medicines and a strong late-stage pipeline focusing on cardiovascular and neurological conditions.

Argus Session date unavailable

+1.69% session move Open Argus

Details

News Market Reaction – IONS

The recorded move for IONS in the trading session of this news was +1.69%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., March 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced its participation in fireside chats at the following investor conferences:

• Guggenheim Virtual Genomic Medicines and Rare Disease Days on Tuesday, April 4, 2023
• 22^nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023

A live webcast of the presentations can be accessed on the Investors & Media section of the Ionis website at www.ionispharma.com. The replay will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals

For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.

To learn more about Ionis, visit www.ionispharma.com and follow us on Twitter @ionispharma.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-upcoming-investor-conferences-301782684.html

SOURCE Ionis Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What investor conferences will Ionis Pharmaceuticals participate in?

Ionis Pharmaceuticals will participate in the Guggenheim Virtual Genomic Medicines and Rare Disease Days on April 4, 2023, and the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023.

How can I access the presentations from Ionis Pharmaceuticals at the investor conferences?

A live webcast of Ionis Pharmaceuticals' presentations can be accessed on their website, and replays will be available within 48 hours.

What is Ionis Pharmaceuticals known for?

Ionis Pharmaceuticals is known for its leadership in RNA-targeted therapy and has pioneered antisense technology, currently offering three marketed medicines.

When were the investor conferences announced by Ionis Pharmaceuticals?

The investor conferences were announced on March 28, 2023.

How many marketed medicines does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals currently has three marketed medicines.